Welcome to LookChem.com Sign In|Join Free

CAS

  • or

81907-82-6

Post Buying Request

81907-82-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

81907-82-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 81907-82-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,1,9,0 and 7 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 81907-82:
(7*8)+(6*1)+(5*9)+(4*0)+(3*7)+(2*8)+(1*2)=146
146 % 10 = 6
So 81907-82-6 is a valid CAS Registry Number.
InChI:InChI=1/C16H21NO3/c1-11(2)17-9-12(18)10-20-16-8-4-5-13-14(16)6-3-7-15(13)19/h3-8,11-12,17-19H,9-10H2,1-2H3

81907-82-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name 5-[2-Hydroxy-3-(isopropylamino)propoxy]-1-naphthol

1.2 Other means of identification

Product number -
Other names 2-Piperidinecarboxylic acid,5-hydroxy

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:81907-82-6 SDS

81907-82-6Downstream Products

81907-82-6Relevant articles and documents

Formate Oxidase (FOx) from Aspergillus oryzae: One Catalyst Enables Diverse H2O2-Dependent Biocatalytic Oxidation Reactions

Tieves, Florian,Willot, Sébastien Jean-Paul,van Schie, Morten Martinus Cornelis Harald,Rauch, Marine Charlène Renée,Younes, Sabry Hamdy Hamed,Zhang, Wuyuan,Dong, JiaJia,Gomez de Santos, Patricia,Robbins, John Mick,Bommarius, Bettina,Alcalde, Miguel,Bommarius, Andreas Sebastian,Hollmann, Frank

supporting information, p. 7873 - 7877 (2019/05/10)

An increasing number of biocatalytic oxidation reactions rely on H2O2 as a clean oxidant. The poor robustness of most enzymes towards H2O2, however, necessitates more efficient systems for in situ H2O2 generation. In analogy to the well-known formate dehydrogenase to promote NADH-dependent reactions, we here propose employing formate oxidase (FOx) to promote H2O2-dependent enzymatic oxidation reactions. Even under non-optimised conditions, high turnover numbers for coupled FOx/peroxygenase catalysis were achieved.

Product inhibition and dose-dependent bioavailability of propranolol in the isolated perfused rat liver preparation

Ghabrial,Nand,Stead,Smallwood,Morgan

, p. 931 - 936 (2007/10/02)

We investigated in the isolated perfused rat liver (IPRL) whether product inhibition of metabolism contributes to the dose-dependent bioavailability of propranolol, a drug with a high, but saturable, hepatic first-pass effect. (±)-Propranolol was infused in the IPRL, using a recirculating design, for three 36-min periods (n = 9). Mean steady-state reservoir, i.e. hepatic inflow concentrations (C(in)), were 4.97, 10.4, and 20.4 μM, respectively. Mean reservoir concentrations of the metabolites 4'-hydroxypropranolol, 5'- hydroxypropranolol, N-desisopropylpropranolol, and naphthoxylactic acid (NLA), a major side-chain-oxidation metabolite, increased disproportionately with propranolol dose, but their production rate did not reach steady state. In separate experiments (n = 4), perfusate containing 7.1, 12.8, and 21.6 μM (±)-propranolol, corresponding to administration rates of 114, 205, and 346 nmol/min, respectively, was passed through the liver for 30 min each using a single-pass design. The bioavailability (hepatic outflow concentration/C(in)) of propranolol increased with C(in) from 0.012 to 0.150 to 0.288 in the recirculating IPRL. In the single-pass IPRL the increase (0.0077 in 0.0669 to 0.136) was significantly less (P 0.001). The greater bioavailability of propranolol in recirculating experiments was attributed to product inhibition since metabolites do not accumulate with the single-pass design. NLA did not appear to be the inhibiting metabolite because in further single-pass experiments with propranolol C(in) of 21.6 μM the presence of NLA (21.6 μM) in perfusate had no effect on propranolol bioavailability (n = 7) compared with control experiments (n = 5). These data suggest that, with the recirculating IPRL, dose-dependent bioavailability of propranolol is due to competitive inhibition of propranolol metabolism by propranolol metabolites, which is distinct from the noncompetitive product inhibition that has been reported to accompany chronic propranolol administration.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 81907-82-6